Clinical trials: Cerebral Disorder
Migraine
A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in the preventive treatment of migraine in pediatric participants 6 to 17 years of age (inclusive at enrollment…
- Trial name
- NCT04530110
- Testing
- Fremanezumab
- Where
- 70 sites in United States, Canada and 7 more
- Volunteers
- 499 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Insomnia, Traumatic Brain Injury
Non-Pharmacological Treatments for Insomnia in Chronic Traumatic Brain Injury
The purpose of this clinical trial is to assess the relative efficacy of two non-pharmacological interventions for insomnia in Veterans suffering from chronic mild traumatic brain injury (mTBI).
- Trial name
- NCT03261674
- Testing
- CBT-I, ABT-I
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- VA Office of Research and Development
Fabry Disease, Chronic Kidney Disease, Stage IV (Severe)
Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme
This study was designed to determine appropriate treatment with Fabrazyme at a biweekly dose of either 1 mg/kg or 3 mg/kg in a population of patients with severe renal disease burden.
- Trial name
- NCT00837824
- Testing
- Fabrazyme (agalsidase beta)
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Genzyme, a Sanofi Company
Urea Cycle Disorder
Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs)
THRIVE is an observational study that will collect information on patients with UCDs. THRIVE will follow enrolled participants for up to 10 years.
- Trial name
- THRIVE (NCT01948427)
- Where
- United States
- Volunteers
- 203 people
- Sponsor
- Amgen
Epilepsy, Partial
Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy
This study is being conducted to determine the effectiveness of a lower monotherapy dose of lamotrigine than that currently approved.
- Trial name
- NCT00355082
- Testing
- lamotrigine, 300 mg/day, lamotrigine, 250 mg/day
- Where
- 103 sites in United States, Argentina and 6 more
- Volunteers
- 226 people
- Sponsor
- GlaxoSmithKline
Cerebral Palsy
Orthotics in Ambulatory Cerebral Palsy
This project will examine the effect of solid ankle foot orthoses (SAFO) on day to day walking activity and life participation of ambulatory children with cerebral palsy.
- Trial name
- SAFO (NCT01527162)
- Testing
- SAFO worn, SAFO not worn
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Seattle Children's Hospital
Epilepsy, Dravet Syndrome
An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes
To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut syndromes.
- Conditions
- Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
- Trial name
- GWPCARE5 (NCT02224573)
- Testing
- GWP42003-P
- Volunteers
- 681 people
- Sponsor
- GW Research Ltd
Cerebral Palsy
Robotic-assisted Therapy to Improve Manual Dexterity in Children With Cerebral Palsy
This is an intervention study including a baseline data collection, 6 weeks of robot-assisted training targeting hand dexterity, and a post-intervention data collection.
- Trial name
- NCT02923167
- Testing
- Robotic-assisted training of the hand
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Spaulding Rehabilitation Hospital
Spastic Cerebral Palsy
Extended-release Epidural Morphine for Acute Post-operative Analgesia Following Selective Dorsal Rhizotomy in Children
The purpose of this proposal is to improve the investigators' current Selective Dorsal Rhizotomy (SDR) analgesia protocol by eliminating or minimizing the use of fentanyl in the post-operative period.
- Trial name
- NCT00955877
- Testing
- Extended-release Epidural morphine (EREM) 80, Extended-release Epidural Morphine (EREM) 120, Control: Saline
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Washington University School of Medicine
Infantile Spasms
A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms
The study consists of cohorts where participants are randomized, in a 2:1 ratio, to 1 of 2 sequences, A and B. In each cohort, Sequence A, comprised of participants, who will receive ascending doses of ganaxolone and ascending…
- Trial name
- NCT00441896
- Testing
- Ganaxolone
- Where
- 15 sites in United States
- Volunteers
- 57 people
- Sponsor
- Marinus Pharmaceuticals
Glial Cell Tumors, Malignant Gliomas
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
Currently, there are few effective treatments for the following aggressive brain tumors: glioblastoma multiforme, anaplastic astrocytoma, gliomatosis cerebri, gliosarcoma, or brainstem glioma.
- Conditions
- Glial Cell Tumors, Malignant Gliomas, Glioblastoma Multiforme, Anaplastic Astrocytoma
- Trial name
- NCT00879437
- Testing
- Valproic acid, Bevacizumab, Radiation therapy
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- Baylor College of Medicine
To Determine Efficacy of the Headpod, Cerebral Palsy
Measuring Head Control Change With 2D Video Analysis After Utilization of Headpod in Children With Poor Head Control
Inclusion Criteria: children ages 2 to 14 years with poor head control and non progressive diagnoses. Exclusion criteria: significant change of status i.e. prolonged hospitalization, surgery; inability to tolerate using Headpod.
- Trial name
- headpod (NCT02764775)
- Testing
- Headpod
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Texas Woman's University
Fabry Disease
Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease
The primary objective of this study was to compare the effect of migalastat (123 milligrams [mg] of migalastat [equivalent to 150 mg of migalastat hydrochloride]) (migalastat) versus placebo on kidney globotriaosylceramide (GL-3).
- Trial name
- NCT00925301
- Testing
- migalastat hydrochloride
- Where
- 28 sites in United States, Argentina and 11 more
- Volunteers
- 67 people
- Sponsor
- Amicus Therapeutics
Cerebral Adrenoleukodystrophy (CALD)
A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)
This trial assessed the efficacy and safety of autologous cluster of differentiation 34 (CD34+) hematopoietic stem cells, transduced ex-vivo with Lenti-D lentiviral vector (also called elivaldogene autotemcel or eli-cel), for the…
- Trial name
- NCT01896102
- Testing
- Lenti-D Drug Product (eli-cel)
- Where
- 8 sites in United States, Argentina and 4 more
- Volunteers
- 32 people
- Sponsor
- Genetix Biotherapeutics Inc.
Epilepsy
Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures
To provide continued treatment of Keppra XR (Levetiracetam XR) and to assess the long term safety of Keppra XR in subjects with partial onset seizures.
- Trial name
- NCT00419393
- Testing
- Keppra XR (Levetiracetam XR)
- Where
- 35 sites in United States, Mexico and 2 more
- Volunteers
- 190 people
- Sponsor
- UCB Pharma
Stroke
Adjunct Low Frequency Repetitive Transcranial Magnetic Stimulation With Physiotherapy Enhance Upper Extremity Function Restoration
Stroke is the leading cause of function disability or impairment. Non-promising functional return from upper limb rehabilitation has been reported.
- Trial name
- NCT02490371
- Testing
- Low frequency rTMS, structured physiotherapy upper limb training
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Queen Elizabeth Hospital, Hong Kong
Amblyopia
Study of Binocular Computer Activities for Treatment of Amblyopia
The purpose of the study is to compare the effectiveness of 1 hour/day of binocular game play 7 days per week with 2 hours/day patching 7 days per week in children 5 to <17
- Trial name
- ATS18 (NCT02200211)
- Testing
- iPad®, Patching 2 hours per day, 7 days per week
- Where
- 2 sites in United States
- Volunteers
- 485 people
- Sponsor
- Jaeb Center for Health Research
Respiratory Failure, Intracranial Hypertension
Safety of Optimal PEEP in NSICU Patients
The investigators aim to demonstrate that use of transpulmonary pressure to guide PEEP management is safe in patients with possible elevations of intracranial pressure.
- Trial name
- NCT03862027
- Testing
- Esophageal Balloon catheter
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of North Carolina, Chapel Hill
Dravet Syndrome (DS)
A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome
The main aim of the study is to learn if soticlestat, when given as an add-on therapy, reduces the number of convulsive seizures in children and young adults with DS.
- Trial name
- NCT04940624
- Testing
- Soticlestat
- Where
- 66 sites in United States, Australia and 16 more
- Volunteers
- 144 people
- Sponsor
- Takeda
Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis
Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
The purpose of this study is to determine a safe dose of BPX-501 gene modified T cells infused after a haplo-identical stem cell transplant to facilitate engraftment and the safety of Rimiducid (AP1903) on day 7 to prevent GVHD.
- Conditions
- Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies
- Trial name
- NCT02231710
- Testing
- BPX-501 and Rimiducid
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Bellicum Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.